We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Study to Examine Whether Rapid COVID-19 Antigen Tests Can Identify Infectious and Asymptomatic Individuals

By LabMedica International staff writers
Posted on 28 Oct 2020
Print article
Image: Study to Examine Whether Rapid COVID-19 Antigen Tests Can Identify Infectious and Asymptomatic Individuals (Photo courtesy of (USC Photo/Gus Ruelas)
Image: Study to Examine Whether Rapid COVID-19 Antigen Tests Can Identify Infectious and Asymptomatic Individuals (Photo courtesy of (USC Photo/Gus Ruelas)
Researchers are using rapid COVID-19 antigen tests in a study to examine their use among first responders and school-aged children, as well as understand whether these tests can identify infectious and asymptomatic individuals.

The study by researchers at the University of Southern California (Los Angeles, CA, USA) will examine the use of coronavirus rapid antigen tests among first responders and school-aged children. The pilot study aims to determine the best methods for using the inexpensive tests with the hope of supporting reopening efforts. Rapid tests have the potential to quickly alert people who are contagious and need to isolate, thereby stopping the chain of transmission. Los Angeles is one of the first metropolitan areas in the country to launch a large-scale pilot study of rapid tests in both symptomatic and asymptomatic participants.

The first phase of the new project kicked off recently with firefighters at the Los Angeles Fire Department receiving three COVID-19 tests at city testing sites: a self-administered rapid antigen test, a lab-based PCR test and an antibody test to identify prior infection. The project, which aims to enroll up to 1,000 first responders, will provide insight into how each test performs and how to best administer these tests to essential frontline workers. The second phase of the project seeks to assess the feasibility, acceptability and accuracy of repeat rapid antigen testing for screening in school-aged children.

Researchers are looking at the pilot studies, focus groups and surveys as avenues to tackle a number of challenges, such as establishing the best way to deploy rapid testing, determining how often a person should repeat testing and identifying the best way to conduct large-scale testing and develop an effective implementation strategy.

“Rapid antigen tests have a lot of promise in our path to reopen schools and businesses because they are cheaper and provide quicker results than PCR tests. But there is a lot we don’t know,” said Neeraj Sood, director of the COVID Initiative at the USC Schaeffer Center for Health Policy & Economics and USC lead on the collaboration. “We want to understand whether rapid antigen tests identify infectious and asymptomatic individuals, whether they can be self-administered and how they can be used for screening at schools and workplaces. We are especially excited to be piloting a new rapid antigen test and mobile app that uses computer vision technology to automatically interpret results.”

Related Links:
University of Southern California

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.